ChartRow logo
Data provided bySource: Twelve Data
TEVA
$42.61+1.99%
as of close, Nov 6, 2026
☾ AH $42.61 +1.99%
Teva Pharmaceutical Industries Limited American Depositary SharesStock · Healthcare
PeersHLNTAKVTRSZTSNBIXUTHR
Share this page

TEVA financial statements

The full income statement, balance sheet, and cash-flow statement for Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +0.7%10Y CAGR −1.3%YoY −1.9%
$17.2B TTM$4.4B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Gross profit

5Y CAGR +3.0%10Y CAGR −2.4%YoY +5.9%
$9.2B TTM$2.4B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y CAGR −4.3%YoY −19.0%
$1.4B TTM$714M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y CAGR −1.2%YoY −46.2%
$506M TTM$233M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m10Y CAGR −4.0%YoY −45.9%
$0.43 TTM$0.20 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y CAGR +6.3%10Y CAGR −11.4%YoY −34.7%
$1.8B TTM$241M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

5Y CAGR −2.8%10Y CAGR −4.2%YoY −11.8%
$534M TTM$120M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +12.5%10Y CAGR −13.3%YoY −48.1%
$1.2B TTM$121M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +6.2%10Y +34.6%YoY +1.6%
1.2B TTM1.2B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Dividend per share

5Y n/m10Y n/m
— FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Every TEVA chart on Trends →

Shares outstanding (point-in-time)

2024-09 1.13B2024-12 1.13B2025-03 1.15B2025-06 1.15B2025-09 1.15B2025-12 1.15B2026-03 1.16B2026-06 1.17B2026-09 1.17B+3.0% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue17.3B+4.3%16.5B+4.4%15.8B+6.2%14.9B-6.0%15.9B-4.7%
8.94B+10.8%8.06B+5.5%7.64B+9.6%6.97B-8.2%7.59B-1.7%
Cost of revenue8.32B-1.9%8.48B+3.4%8.20B+3.1%7.95B-4.0%8.28B-7.3%
Research & development1.01B+1.5%998M+4.7%953M+13.7%838M-13.3%967M-3.0%
Selling, general & administrative3.97B+7.3%3.70B+5.8%3.50B+1.5%3.44B-2.4%3.53B-3.9%
General & administrative1.29B+10.9%1.16B-0.1%1.16B-1.5%1.18B+7.4%1.10B-6.3%
Selling & marketing2.69B+5.7%2.54B+8.8%2.34B+3.1%2.27B-6.8%2.43B-2.8%
Restructuring225M+204.1%74.0M-33.3%111M-24.0%146M+9.8%133M+10.8%
Amortization of intangibles581M-1.2%588M-4.5%616M-15.8%732M-8.7%802M-21.4%
Operating income2.16B+811.9%-303M-170.0%433M+119.7%-2.20B-228.0%1.72B+148.0%
Interest expense916M-8.6%1.00B-2.6%1.03B+10.6%930M+4.4%891M-1.1%
Other non-operating income-934M+4.8%-981M+7.2%-1.06B-9.4%-966M+8.7%-1.06B-26.9%
Equity-method income15.0M+1400.0%1.00M-50.0%2.00M-90.5%21.0M+133.3%9.00M-93.5%
Pre-tax income1.22B+195.2%-1.28B-105.8%-624M+80.3%-3.16B-580.7%658M+114.9%
Income tax-180M-126.6%676M+9757.1%-7.00M+98.9%-643M-404.7%211M+225.6%
1.41B+186.0%-1.64B-193.2%-559M+77.1%-2.45B-686.6%417M+110.5%
Net income to non-controlling interest7.00M+102.2%-320M-471.4%-56.0M-5.7%-53.0M-235.9%39.0M+135.8%
Net income to common1.41B+186.0%-1.64B-193.2%-559M+77.1%-2.45B-686.6%417M+110.5%
$1.21+183.4%-$1.45-190.0%-$0.50+77.3%-$2.20-678.9%$0.38+110.4%
EPS (basic)$1.23+184.8%-$1.45-190.0%-$0.50+77.3%-$2.20-678.9%$0.38+110.4%
Weighted-avg shares (basic)1.15B+1.2%1.13B+1.1%1.12B+0.8%1.11B+0.7%1.10B+0.6%
Weighted-avg shares (diluted)1.16B+2.8%1.13B+1.1%1.12B+0.8%1.11B+0.3%1.11B+1.1%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
13.9B+11.1%12.6B+0.5%12.5B+3.6%12.1B-4.2%12.6B-3.3%
Cash & equivalents3.56B+7.8%3.30B+2.3%3.23B+15.2%2.80B+29.4%2.17B-0.6%
Accounts receivable3.71B+21.2%3.06B-10.2%3.41B-7.8%3.70B-18.4%4.53B-1.1%
Inventory3.18B+5.7%3.01B-25.2%4.02B+4.9%3.83B+0.4%3.82B-13.3%
Prepaid expenses1.12B+11.5%1.01B-19.8%1.25B+8.0%1.16B+8.1%1.07B+13.8%
Other current assets539M+31.8%409M-18.8%504M-8.2%549M-43.1%965M+35.9%
40.7B+3.6%39.3B-9.6%43.5B-1.2%44.0B-7.7%47.7B-5.9%
Property, plant & equipment4.08B-10.9%4.58B-20.3%5.75B+0.2%5.74B-4.1%5.98B-5.0%
Operating lease right-of-use345M-6.0%367M-7.6%397M-5.3%419M-15.4%495M-11.4%
Goodwill16.0B+5.6%15.1B-11.8%17.2B-2.6%17.6B-12.0%20.0B-2.8%
Intangible assets3.78B-14.4%4.42B-18.0%5.39B-14.1%6.27B-16.0%7.47B-16.3%
Deferred tax assets2.19B+21.8%1.80B-0.7%1.81B+24.3%1.46B+144.6%596M-14.2%
Other non-current assets405M-12.3%462M-1.7%470M+6.6%441M-14.4%515M-4.3%
13.5B+5.2%12.8B+4.5%12.2B+6.8%11.5B+4.0%11.0B-16.2%
Accounts payable2.53B+14.9%2.20B-15.3%2.60B+37.9%1.89B+11.9%1.69B-4.0%
Accrued liabilities
————23.0M
Short-term & current debt1.82B+2.2%1.78B+6.5%1.67B-20.7%2.11B+47.9%1.43B-55.3%
Current lease liability288M-2.7%296M-7.5%320M-8.3%349M-16.1%416M-13.2%
Other current liabilities1.18B+15.9%1.02B-2.3%1.04B+3.9%1.00B+11.3%903M-3.2%
32.8B-2.3%33.6B-4.9%35.4B-0.2%35.4B-2.8%36.4B-8.0%
Long-term debt15.0B-6.3%16.0B-11.9%18.2B-4.9%19.1B-11.6%21.6B-4.9%
Non-current lease liability288M-2.7%296M-7.5%320M-8.3%349M-16.1%416M-13.2%
Operating lease liability (total)382M-0.3%383M-8.2%417M-5.7%442M-15.8%525M-11.8%
Finance lease liability (total)43.0M+87.0%23.0M-28.1%32.0M+45.5%22.0M-12.0%25.0M+19.0%
Other non-current liabilities3.81B-5.5%4.03B+0.2%4.02B+1.9%3.94B+53.0%2.58B+15.1%
Total non-current liabilities19.4B-6.9%20.8B-9.9%23.1B-3.5%23.9B-5.7%25.4B-3.9%
7.91B+47.2%5.37B-28.4%7.51B-3.8%7.80B-24.1%10.3B+2.5%
Common stock58.0M+0.0%58.0M+1.8%57.0M+0.0%57.0M+0.0%57.0M+0.0%
Additional paid-in capital28.1B+1.3%27.8B-0.2%27.8B+0.4%27.7B+0.5%27.6B+0.4%
Retained earnings-13.8B+9.3%-15.2B-12.1%-13.5B-4.3%-13.0B-23.2%-10.5B+3.8%
Treasury stock4.13B+0.0%4.13B+0.0%4.13B+0.0%4.13B+0.0%4.13B+0.0%
Accumulated other comprehensive income-2.39B+24.0%-3.15B-16.7%-2.70B+5.0%-2.84B-5.8%-2.68B-11.8%
Non-controlling interest4.00M-42.9%7.00M-98.9%620M-21.9%794M-17.8%966M-6.7%
Total equity incl. non-controlling7.91B+47.1%5.38B-33.8%8.13B-5.5%8.60B-23.5%11.2B+1.7%
Total liabilities & equity40.7B+3.6%39.3B-9.6%43.5B-1.2%44.0B-7.7%47.7B-5.9%
Common shares issued1.26B+1.4%1.24B+1.1%1.23B+0.8%1.22B+0.7%1.21B+0.6%
Common shares outstanding1.15B+1.5%1.13B+1.1%1.12B+0.9%1.11B+0.7%1.10B+0.6%
Shares outstanding (cover)1.15B+1.4%1.13B+1.1%1.12B+0.9%1.11B+0.7%1.10B+0.6%
Treasury shares107M+0.0%107M+0.9%106M+0.0%106M+0.0%106M+0.0%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
1.65B+32.2%1.25B-8.8%1.37B-14.0%1.59B+99.2%798M-34.4%
Depreciation & amortization1.00B-5.4%1.06B-8.2%1.15B-11.9%1.31B-1.7%1.33B-14.6%
Intangible amortization581M-1.2%588M-4.5%616M-15.8%732M-8.7%802M-21.4%
Share-based compensation157M+27.6%123M+1.7%121M-2.4%124M+4.2%119M-7.8%
Deferred income taxes—-418M-22.9%-340M+68.3%-1.07B-1718.6%-59.0M+83.1%
Change in inventory152M-8.4%166M+212.9%-147M+9.8%-163M-142.9%380M+826.8%
Other operating activities81.0M-85.5%560M+818.0%61.0M+167.0%-91.0M-668.8%16.0M-84.0%
737M-6.9%792M-18.2%968M+47.6%656M-56.9%1.52B+76.5%
Capital expenditure501M+0.6%498M-5.3%526M-4.0%548M-2.5%562M-2.8%
Free cash flow1.15B+53.3%749M-11.0%842M-19.2%1.04B+341.5%236M-63.0%
Acquisitions0.00-100.0%15.0M0.00-100.0%7.00M0.00
Sales/maturities of investments42.0M+5.0%40.0M0.00-100.0%4.00M-97.7%172M+1333.3%
Other investing activities-5.00M-150.0%-2.00M-140.0%5.00M0.00+100.0%-1.00M+91.7%
-2.15B-20.1%-1.79B+6.4%-1.91B-28.6%-1.49B+31.5%-2.17B-15.2%
Long-term debt issued2.30B0.00-100.0%2.45B0.00-100.0%4.97B
Long-term debt repaid4.11B+150.6%1.64B-60.5%4.15B+203.3%1.37B-79.4%6.65B+255.4%
Common stock issued0.000.000.000.000.00
Common stock repurchased0.000.000.000.000.00
Dividends paid——0.000.000.00
Other financing activities41.0M+612.5%-8.00M+96.2%-212M-79.7%-118M-1866.7%-6.00M-20.0%
FX effect on cash21.0M+112.1%-174M-480.0%-30.0M+75.6%-123M+3.9%-128M-1700.0%
Net change in cash256M+245.9%74.0M-81.2%393M-38.2%636M+2928.6%21.0M-89.6%
Interest paid950M-5.4%1.00B-6.9%1.08B+13.7%948M+3.8%913M+7.9%
Income taxes paid—471M+58.1%298M-45.1%543M+9.7%495M-30.2%
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap35.9B+43.6%25.0B+113.5%11.7B+15.5%10.1B+14.6%8.84B-16.5%
P/E25.5×———21.2×
P/S2.1×+37.7%1.5×+97.1%0.8×+14.5%0.7×+20.2%0.6×-12.4%
P/B4.5×-2.5%4.7×+175.4%1.7×+46.2%1.2×+34.4%0.9×-18.5%
P/FCF31.3×-6.3%33.4×+73.3%19.2×-2.3%19.7×-47.4%37.4×+125.8%
Earnings yield3.9%———4.7%
FCF yield3.2%+6.7%3.0%-42.3%5.2%+2.4%5.1%+90.0%2.7%-55.7%
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Richard Francis$19.2M$55M$6.6M$323.42$156.35
FY2024Richard Francis$15.5M$40.9M$5.6M$228.39$118.45
FY2023Richard Francis$25.7M$26.2M$4.5M$108.19$109.31
FY2022Kare Schultz$15.5M$17.2M$4M$94.51$107.97
FY2021Kare Schultz$14.7M$7.6M$3.7M$83.01$113.11
FY2020Kare Schultz$15.7M$10.9M$4M——

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: TEVA’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all TEVA filings on SEC EDGAR → Not investment advice.